Deniz Erdem

Deniz Erdem

Auto-generated profile, based on publicly available information

Deniz Erdem

Department of Critical Care, University of Health Sciences, Ankara Bilkent City Hospital, Ankara, Turkiye

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2022 in The Journal of Infection in Developing Countries
Verified
Journal Article
Open access
PDF file
İMİpek Mumcuoğlu
İpek Mumcuoğlu
HÇHatice Çağlar
Hatice Çağlar
DEDeniz Erdem
Deniz Erdem
AAAdalet Aypak
Adalet Aypak
PGPınar Gün
Pınar Gün
BDBedia Dinç
Bedia Dinç
Introduction: Secondary Bacterial Infections (SBIs) of the respiratory system are one of the biggest medical concerns in patients undergoing hospitalization with a diagnosis of COVID-19. This study aims to provide relevant data for the initiation of appropriate empirical treatment after examining the etiology and antimicrobial resistance of SBIs in COVID-19 patients under care in the Intensive Care Units (ICUs) in the largest pandemic hospital of our country. Methodology: Between March 16, 2020 and December 31, 2021, 56,993 COVID patients were hospitalized, of which 7684 were admitted to ICUs. A total of 1513 patients diagnosed with SBIs have been included in this study. During the course of the study, demographic data, clinical course, etiology and antimicrobial resistance data of all patients were collected. Results: The most common causative agents of SBIs were inferred as Acinetobacter baumanii (35.1%), Staphylococcus aureus (15.2%), Klebsiella pneumoniae (12.3%) and Pseudomonas aeruginosa (10.4%). The isolation rates of carbapenem-resistant and colistin-resistant A. baumannii, K. pneumoniae and P. aeruginosa were 83.7%; 42.7%, 79.2%, and 5.6%, 42.7%, 1.7%, respectively. Acinetobacter pittii clustering was seen in one of the ICUs in the hospital. Multidrug resistant 92 (5.4%) Corynebacterium striatum isolates were also found as a causative agent with increasing frequency during the study period. Conclusions: SBI of the respiratory system is one of the major complications in patients hospitalized with COVID-19. The antimicrobial resistance rates of the isolated bacteria are generally high, which indicates that more accurate use of antibacterial agents is necessary for SBIs in patients hospitalized with COVID-19 diagnosis.

7 February 2022 in The Anatolian Journal of Cardiology
Verified
Journal Article
Open access
SBSerdal Baştuğ
Serdal Baştuğ
ATAnkara- Turkey
Ankara- Turkey
CCCavdarli Cavdarli
Cavdarli Cavdarli
ABAliye Bastug
Aliye Bastug
IŞİrFan Şencan
İrFan Şencan
HBHürrem Bodur
Hürrem Bodur
The impact of the coronavirus disease 2019 (COVID-19) pandemic has been unceasingly ongoing worldwide. Recent bioinformatics analysis and epidemiologic studies have highlighted that the functional polymorphisms on the angiotensin converting enzyme (ACE) gene may have an impact on the clinical progress of COVID-19. In this study, we aimed to determine the impact of the ACE1 gene I/D polymorphism and ACE2 peptidase-2 domain variants on disease severity. Hundred patients with confirmed COVID-19 related pneumonia [50 patients with severe disease in intensive care unit (ICU) and 50 patients not in ICU] were compared on the basis of genetic and clinical characteristics. Genomic DNA was purified from peripheral blood lymphocytes with an automated QIA symphony DSP DNA Mini-Kit. The Sanger sequencing analysis was performed. The frequencies of ACE1 gene polymorphism and ACE2 PD variants were compared in patients hospitalized in ICU and those not in ICU. The Statistical Package for Social Sciences version 22.0 was used for statistical analysis. The sequencing analysis of the ACE2 gene exon 1 and 2 revealed none of the polymorphisms investigated or any other variants in the present cohort. The frequencies of the ACE1 ID, DD, and II genotypes were 51%, 31%, and 18%, respectively. The frequency of the D allele was similar between the ICU and non-ICU groups (50.4% versus 49.6%). Older age and the presence of advanced stage radiologic abnormalities on admission were detected as independent predictors of ICU requirement. No effect of any ACE1 gene polymorphism on predicting ICU requirement was detected. To the best of our knowledge, this is the first study investigating the impact of ACE gene polymorphisms on clinical severity of COVID-19 in a Turkish cohort.

22 November 2023 in Thoracic Research and Practice
Verified
Journal Article
Open access
SGSinem Gungor
Sinem Gungor
ÖEÖzlem Ediboğlu
Özlem Ediboğlu
ÖMÖzlem Yazıcıoğlu Moçin
Özlem Yazıcıoğlu Moçin
NANalan Adıgüzel
Nalan Adıgüzel
ETEylem Tunçay
Eylem Tunçay
FTFiliz Tüzüner
Filiz Tüzüner
COVID-19,intensive care,intensive care unit,pandemic,follow-up

25 September 2022 in Journal of Health Sciences and Medicine
Verified
Journal Article
Open access
PDF file
EUElmas Uysal
Elmas Uysal
FSFatih Segmen
Fatih Segmen
PUPınar Ulubaşoğlu
Pınar Ulubaşoğlu
EZEmine Nilgün Zengin
Emine Nilgün Zengin
DEDeniz Erdem
Deniz Erdem
Aim: The mortality and morbidity of COVID-19 disease are higher in patients with comorbidities. In this study, we staged patients with chronic renal failure hospitalized in the intensive care unit (ICU) and aimed to evaluate the process of the disease according to the stage of failure. Material and Method: The medical records of 249 patients followed in Ankara City Hospital MH3 ICU were reviewed retrospectively. The patients were divided into three stages according to their estimated glomerular filtration rate (e-GFR) value (stage 1: e-GFR≥90 ml/min/1.73 m², stage-2: e-GFR: 15-89 ml/min/1.73 m², stage- 3: e-GFR≤15 ml/min/1.73 m²). Data such as age, gender, comorbidity status, length of stay in the ICU, duration of mechanical ventilation, and mortality rate of the patients were recorded. Patients who were evaluated as stage-2 were also classified into 3 stages (stage-2a: e-GFR: 60-89 ml/min/1.73 m², stage-2b: e-GFR:30-59 ml/min/1.73 m², stage-2c: e-GFR: 15-29 ml/min/1.73 m²) and evaluated with the same parameters. Results: The mean age of all patients was 71 years. It was found that the intubation rate was higher (p=0.012) and the mortality rate was higher (p=0.003) in patients evaluated as stage-3. APACHE II and SOFA scores were higher than the other groups (p=

30 September 2025 in The Anatolian Journal of Anesthesiology and Intensive Care
Verified
Journal Article
Open access
CGCanan Gönen
Canan Gönen
SÖSevil Baltacı Özen
Sevil Baltacı Özen
DCDuygu Kayar Calili
Duygu Kayar Calili
DEDeniz Erdem
Deniz Erdem
ITIşıl Ozkocak Turan
Işıl Ozkocak Turan
Background: COVID-19 is associated with high mortality in critically ill patients due to an exaggerated inflammatory response characterized by a cytokine storm. In this context, the anti-inflammatory properties of corticosteroids have emerged as a significant therapeutic option. This study retrospectively evaluated COVID-19 patients who received low-dose dexamethasone therapy in the intensive care unit, and the relationship between survival status and changes in laboratory parameters was investigated.Materials and Methods: Between June and August 2020, 80 patients with a confirmed diagnosis of COVID-19 by RT-PCR who received low-dose dexamethasone therapy (6 mg/day, up to 10 days) in the intensive care unit were analyzed. Patients were divided into two groups according to their clinical outcomes: survivors (n=41) and non-survivors (n=39). Laboratory measurements were recorded at two time points: within the first 24 hours of ICU admission (T0) and on day 5 ±2 (T1). Percentage changes were calculated.Results: The mean age of the survivor group was higher than that of the non-survivor group (77.1 vs. 62.3 years; p<0.001). At T0, WBC levels were lower in the non-survivor group (p=0.027). Regarding the change from T0 to T1 in IL-6 levels, a decrease of 76.6% was observed in the non-survivor group and 54.5% in the survivor group (p=0.045). Ferritin levels increased in the survivor group but decreased in the non-survivor group (p=0.001). D-dimer levels showed a marked increase in the survivor group, whereas a decrease was observed in the non-survivor group (p<0.001).Conclusion: The literature has strongly demonstrated that corticosteroids can improve survival in patients with severe COVID-19. The unique contribution of this study lies in revealing the changes in laboratory parameters between survival groups under dexamethasone therapy. Although the findings do not establish a direct relationship with mortality, they may serve as hypothesis-generating data that contribute to understanding the heterogeneity of clinical responses.

26 July 2022 in Anatolian Current Medical Journal
Verified
Journal Article
Closed access
PDF file
EUElmas Uysal
Elmas Uysal
FSFatih Segmen
Fatih Segmen
GKGamze Kiliçarslan
Gamze Kiliçarslan
DEDeniz Erdem
Deniz Erdem
Background: It is known that COVID-19 has a worse and poorer progression, which often might lead to death in those with comorbidities. Multiple studies have recently examined the clinical course of cancer patients with COVID-19 and new guidelines have been developed to manage this group of patients. This study aimed to evaluate the clinical course and mortality rate of cancer patients admitted to the intensive care unit (ICU) for COVID-19. Material and Method: The demographic characteristics, detailed medical history and laboratory findings of 140 patients with malignancy, who were treated in the COVID-19 Intensive Care Unit of Ankara City Hospital, were evaluated retrospectively. Gender, age, comorbidity, length of stay in the ICU, mortality rates, length of stay on a mechanical ventilator, cytokine storm scores, ferritin, interleukin 6 (IL-6), C-reactive protein (CRP), procalcitonin (PCT), D-dimer, lactate dehydrogenase (LDH), lymphocyte count and treatment options were compared. The patients were divided into two groups: solid and hematological malignancies. Results: One hundred eight of 140 patients were diagnosed with solid organ malignancy and 32 with hematological malignancy. The most common comorbidity was found to be hypertension. A total of 94 patients died during their ICU stay. While the most common solid organ malignancies were malignancies of the lower gastrointestinal tract and lung cancers, multiple myeloma (MM) was the most common hematological malignancy. There was no significant difference between the two groups in terms of cytokine storm scores , duration of hospitalization and mechanical ventilation. Levels of Ferritin and LDH were found to be significantly higher in patients with hematological malignancies, while D-dimer was significantly higher in solid organ malignancies. A high level of CRP and IL-6 was associated with COVID-19 mortality. Lymphopenia was associated with increased mortality in patients with solid organ malignancy. However, there was no difference in mortality rate among both groups. Although the mortality was significantly higher in the patient group receiving chemotherapy, there were no significant differences in mortality for the duration of receiving chemotherapy. Conclusion: The results of this study suggested that cancer was associated with severe clinical outcomes and a 67% mortality rate among patients with COVID-19. However, despite the changes in patients’ demographic, clinical and laboratory characteristics, no difference in mortality rate was detected in patients with hematological and solid organ malignancies due to COVID-19 infection.